Courses

Managing Hemorrhagic Complications and Bleeding Risks Associated with Platelet P2Y12 Inhibitor Therapy

Managing Hemorrhagic Complications and Bleeding Risks Associated with Platelet P2Y12 Inhibitor Therapy

Antiplatelet therapy is an essential part of secondary prevention of cardiovascular events.  In particular, dual antiplatelet therapy (DAPT) — the combination of aspirin with an oral P2Y12 receptor antagonist — is the predominant approach in patients with acute coronary syndromes (ACS), coronary-artery stenting, or previous myocardial infarction (MI). The three oral P2Y12 receptor antagonists that are in use are clopidogrel, ...
View Course
Therapeutic Advances for the Management of Pediatric Patients with Atopic Dermatitis

Therapeutic Advances for the Management of Pediatric Patients with Atopic Dermatitis

This continuing medical education program is derived from material presented in an AcademicCME-sponsored symposium held in conjunction with the 2020 AAP Virtual National Conference & Exhibition. This continuing medical education program will highlight therapeutic advances for the management of patients with atopic dermatitis, focusing primarily on the pediatric population. The expert faculty, chaired by Dr. Lawrence F. Eichenfield, will first ...
View Course
The Science and Guidelines Concerning COVID-19 and Biosimilar Therapeutics for Inflammatory Conditions

The Science and Guidelines Concerning COVID-19 and Biosimilar Therapeutics for Inflammatory Conditions

In this module, Rowena Schwartz PharmD, BCOP, along with Beth Faiman, PhD, MSN, APN-BC, AOCN, course chair, will provide current data for treating patients with biosimilars in the era of the COVID-19 pandemic. The expert faculty will highlight the evolving impact of COVID-19 on healthcare expenditure, including availability of services and financial burdens. Therapeutic considerations amidst the pandemic will be ...
View Course
Incorporating Biosimilars into Treatment Plans for Inflammatory Rheumatological Disorders

Incorporating Biosimilars into Treatment Plans for Inflammatory Rheumatological Disorders

In this module, Jonathan Kay, MD, along with Beth Faiman, PhD, MSN, APN-BC, AOCN, course chair, will review current clinical trial data, including registry data, of biosimilar therapeutics in patients with rheumatological disorders. The expert faculty will analyze recent studies, debating the clinical implications of each. Terms such as biosimilarity, changing and switching will also be clarified as they relate ...
View Course
Incorporating Biosimilars into Treatment Plans for Inflammatory Gastroenterological Disorders

Incorporating Biosimilars into Treatment Plans for Inflammatory Gastroenterological Disorders

In this module, Francis A. Farraye, MD, MSc, along with Beth Faiman, PhD, MSN, APN-BC, AOCN, course chair, will analyze current clinical trial of data of biosimilar agents, particularly in gastroenterological disorders. Efficacy and immunogenicity in both induction and switching studies will be reviewed, and clinical relevance debated. The expert faculty will also relay societal guidelines regarding the use of ...
View Course
Patient Education and Shared Decision-Making Specific to Biosimilar Therapeutics: The Why and The How

Patient Education and Shared Decision-Making Specific to Biosimilar Therapeutics: The Why and The How

In this module, Amy Goodrich, RN, BSN, MSN, CRNP-AC, along with Beth Faiman, PhD, MSN, APN-BC, AOCN, course chair, will highlight best practices for shared decision making as well as strategies for administering comprehensive patient education to promote adherence to biosimilar agents. The expert faculty will review methods to minimize the ‘nocebo’ effect and improve outcomes in patients with inflammatory ...
View Course
Biosimilars 101: The Science, Approval Process, and Extrapolation of Clinical Data and Indications

Biosimilars 101: The Science, Approval Process, and Extrapolation of Clinical Data and Indications

In this module, Ali McBride, PharmD, MS, BCPS, BCOP, along with Beth Faiman, PhD, MSN, APN-BC, AOCN, course chair, will provide background information regarding the science and approval process of biosimilar agents in inflammatory conditions. Topics such as immunogenicity and the extrapolation framework will also be reviewed in a discussion-based format. At the conclusion of this 30-minute interview segment, learners ...
View Course
Strategies for the Long-Term Treatment of SMA to Optimize Patient Outcomes

Strategies for the Long-Term Treatment of SMA to Optimize Patient Outcomes

In this module, Perry Shieh, MD, PhD, along with Claudia Chiriboga, MD, MPH, course chair, will review strategies for the long-term treatment of SMA to optimize patient outcomes. The expert faculty will discuss long-term efficacy and safety data in order to develop effective SMA patient management strategies with the interprofessional team and identify available resources for optimal care while the ...
View Course
The Benefits and Long-Term Effects of Presymptomatic Treatment

The Benefits and Long-Term Effects of Presymptomatic Treatment

In this module, Julie Parsons, MD, along with Claudia Chiriboga, MD, MPH, course chair, will review the benefits and long-term effects of presymptomatic treatment for patients with spinal muscular atrophy (SMA). The faculty will discuss the benefits of early disease diagnosis and how to implement presymptomatic treatment in infants with SMA. Upon completion of this 30-minute module, clinicians will gain ...
View Course
Review of Current and Emerging Therapeutic Options for Patients with SMA

Review of Current and Emerging Therapeutic Options for Patients with SMA

In this module, Basil Darras, MD, along with Claudia Chiriboga, MD, MPH, course chair, will analyze current and emerging therapeutic options for patients with spinal muscular atrophy (SMA). The faculty will review recent data of both available and investigational therapeutic options for the treatment of patients with SMA. Upon completion of this 30-minute module, learners will gain insight into current ...
View Course
Loading...